Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin

被引:84
作者
Ertl, B
Platzer, P
Wirth, M
Gabor, F
机构
[1] Univ Vienna, Inst Pharmaceut Technol, A-1090 Vienna, Austria
[2] Univ Vienna, Inst Pharmaceut Chem, A-1090 Vienna, Austria
关键词
camptothecin; microencapsulation; poly(D; L-lactic-co-glycolic acid); chemotherapy;
D O I
10.1016/S0168-3659(99)00122-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Camptothecin (CPT) and its water-insoluble derivatives are known as topoisomerase-I inhibitors exhibiting high antitumoral activity against a wide spectrum of human malignancies. Until now clinical application of CPT is restricted by insolubility and instability of the drug in its active lactone form resulting in less antitumor potency and poor bioavailability. For these reasons CPT-loaded-microspheres were prepared by the solvent evaporation method using the H-series of poly(D,L-lactide-co-glycolide) (H-PLGA), which contain more carboxylic acid end chains and hydrate faster than the non-K-series. At 1.2% CPT-payload the drug was molecular dispersed throughout the matrix whereas at higher CPT-payload the amount of crystalline CPT-islets increased with the CPT content. The release pattern of CPT was biphasic comprising a first burst effect delivering 20-35% of the payload and increasing with drug-loading. This phase was followed by sustained delivery of CPT releasing 40-75% of the payload within 160 h. In comparison to PLGA-microspheres, the CPT-release rate from H-PLGA was twofold higher and accelerated. The active CPT-lactone was maintained during preparation, storage and release due to hindered diffusion of acidic oligomers among other mechanisms. Thus stabilization and sustained release of CPT from PLGA-microspheres might reduce local toxicity combined with prolonged efficacy offering new perspectives in CPT chemotherapy. (C) 1999 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:305 / 317
页数:13
相关论文
共 20 条
[1]   PREPARATION AND CHARACTERIZATION OF MICROOSPHERES CONTAINING THE ANTI-INFLAMMATORY AGENTS, INDOMETHACIN, IBUPROFEN, AND KETOPROFEN [J].
BODMEIER, R ;
CHEN, H .
JOURNAL OF CONTROLLED RELEASE, 1989, 10 (02) :167-175
[2]   LIPID BILAYER PARTITIONING AND STABILITY OF CAMPTOTHECIN DRUGS [J].
BURKE, TG ;
MISHRA, AK ;
WANI, MC ;
WALL, ME .
BIOCHEMISTRY, 1993, 32 (20) :5352-5364
[3]   PREFERENTIAL BINDING OF THE CARBOXYLATE FORM OF CAMPTOTHECIN BY HUMAN SERUM-ALBUMIN [J].
BURKE, TG ;
MI, ZH .
ANALYTICAL BIOCHEMISTRY, 1993, 212 (01) :285-287
[4]  
Conover CD, 1997, ANTICANCER RES, V17, P3361
[5]   Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker [J].
Conover, CD ;
Greenwald, RB ;
Pendri, A ;
Gilbert, CW ;
Shum, KL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (05) :407-414
[6]   PREPARATION OF MAPPICINE KETONES FROM CAMPTOTHECINS - CHEMISTRY OF THE CAMPTOTHECIN E-RING [J].
FORTUNAK, JMD ;
MASTROCOLA, AR ;
MELLINGER, M ;
WOOD, JL .
TETRAHEDRON LETTERS, 1994, 35 (32) :5763-5764
[7]   Ketoprofen-poly(D,L-lactic-co-glycolic acid) microspheres: influence of manufacturing parameters and type of polymer on the release characteristics [J].
Gabor, F ;
Ertl, B ;
Wirth, M ;
Mallinger, R .
JOURNAL OF MICROENCAPSULATION, 1999, 16 (01) :1-12
[8]   DNA TOPOISOMERASE-I TARGETED CHEMOTHERAPY OF HUMAN-COLON CANCER IN XENOGRAFTS [J].
GIOVANELLA, BC ;
STEHLIN, JS ;
WALL, ME ;
WANI, MC ;
NICHOLAS, AW ;
LIU, LF ;
SILBER, R ;
POTMESIL, M .
SCIENCE, 1989, 246 (4933) :1046-1048
[9]  
GUPTA PK, 1993, PHARM PARTICULATE CA, P135
[10]   In vitro biocompatibility of bioresorbable polymers: Poly(L,DL-lactide) and poly(L-lactide-co-glycolide) [J].
Ignatius, AA ;
Claes, LE .
BIOMATERIALS, 1996, 17 (08) :831-839